logo
eClinicalWorks and healow Genie to Assist Large Georgia Pain Management Institute Manage Substantial Influx of Patient Calls

eClinicalWorks and healow Genie to Assist Large Georgia Pain Management Institute Manage Substantial Influx of Patient Calls

Business Wire7 days ago

WESTBOROUGH, Mass.--(BUSINESS WIRE)-- eClinicalWorks®, the largest ambulatory cloud EHR, today announced that Alliance Spine and Pain Centers has selected the first-of-its-kind, EHR-agnostic, AI-powered contact center solution, healow® Genie, to manage the rising number of incoming patient calls. The AI-powered contact center solution will effectively manage a large volume of calls and quickly provide a resolution to common patient queries like requests, refills, references, and billing questions. The AI technology will allow medical staff to focus on complex questions that require immediate attention.
'I believe that healow Genie can help us data mine our calls,' said Cheraire Lyons, Vice President of Revenue Cycle at Alliance Spine and Pain Centers. 'What I mean by that is understanding what type of calls are coming in and directing them to the right place the first time. Being able to answer those calls more efficiently allows us to speed up wait times.'
She further added, 'It will significantly help improve patient experience, knowing that they can call and talk to someone about a procedure they're preparing to have or just getting feedback on questions related to their care, making them feel heard.'
Alliance Spine and Pain Centers has 20 locations across Georgia, and its team, which includes best-in-class physicians, medical professionals, and administrators, is dedicated to bringing relief to people suffering from chronic pain. One of its biggest challenges is managing the ever-increasing number of incoming patient calls. While the practice has two call centers, one dedicated to handling billing questions, the long wait time makes the patients call back or leave a voicemail. The medical staff often must manage voicemails or telephone encounters simultaneously.
By offering patients 24/7 access to vital health information via voice call, text, or chatbot with zero waiting time, healow Genie can significantly help enhance patient satisfaction, reduce administrative burdens on staff, and lower overall operational costs.
"By transforming the way medical practices connect with their patients, healow Genie is bringing the future of patient engagement to the present," said Girish Navani, CEO of eClinicalWorks. 'The integration with healow Genie can manage routine tasks like appointment scheduling and medication refills, allowing medical staff to focus on delivering quality care.'
healow Genie offers a comprehensive suite of features, including patient self-service, an intelligent assistant, automated after-hours service, and conversational smart campaigns.
Hear from Cheraire Lyons in this video to learn more about the practice's story and how they expect healow Genie to improve efficiency and patient satisfaction.
About Alliance Spine and Pain Centers
With 20 locations across Georgia, Alliance Spine and Pain Centers is dedicated to bringing real relief to people suffering from chronic pain. The practice's team includes best-in-class physicians, medical professionals, and administrators. Together, they provide their patients with the best pain management treatment while leading the way to the future of pain relief. For more information, visit www.spinepains.com.
About eClinicalWorks
eClinicalWorks ® was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks leads the nation in innovation with cloud-based solutions for Electronic Health Records and Practice Management. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 180,000 providers and nearly 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit www.eclinicalworks.com, follow us on LinkedIn, Facebook and X/Twitter, or call (866) 888-6929.
About healow Genie
healow® Genie is a first-of-its-kind, EHR-agnostic, AI-powered contact center solution designed to enhance patient engagement by providing patients 24/7 access to vital health information via voice call, text, or chatbot. It offers a comprehensive suite of features, including patient self-service, intelligent assistant, automated after-hours service, and conversational smart campaigns. Genie improves patient satisfaction, reduces administrative burdens on staff, and lowers overall operational costs. For more information, visit genie.healow.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Yahoo

time44 minutes ago

  • Yahoo

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David Veitch, Basilea's Chief Executive Officer, stated: 'This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients facing life-threatening infections. We congratulate our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need.' The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region. Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 amounted to USD 562 million, a 19 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 About Cresemba® (isavuconazole) Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This press release can be downloaded from References IQVIA Analytics Link, December 2024. In-market sales reported as moving annual total (MAT) in US dollar. European Public Assessment Report (EPAR) Cresemba: [Accessed: June 04, 2025] Summary of Product Characteristics (SmPC) Cresemba: [Accessed: June 04, 2025] Full US prescribing information: [Accessed: June 04, 2025] The registration status and approved indications may vary from country to country. Attachment Press release (PDF)

Dr. Reddy's shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda
Dr. Reddy's shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda

Business Upturn

timean hour ago

  • Business Upturn

Dr. Reddy's shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda

By Aman Shukla Published on June 5, 2025, 09:29 IST Shares of Dr. Reddy's Laboratories rose 4% in morning trade after the company announced a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilars. The two companies will co-develop and manufacture a biosimilar version of Keytruda® (pembrolizumab), a blockbuster immunotherapy drug used to treat various cancers. Keytruda® generated global sales of US$29.5 billion in 2024, highlighting the significant market potential for its biosimilar version. Through this partnership, Dr. Reddy's and Alvotech aim to accelerate development timelines and expand access to affordable cancer treatments across international markets. As part of the agreement, both firms will jointly invest in R&D, manufacturing, and regulatory processes. Each partner retains global commercialization rights, with certain market exceptions, allowing for broad market reach while optimizing operational efficiency. Dr. Reddy's Laboratories shares opened at ₹1,264.20 and at the time of writing, surged to an intraday high of ₹1,303.40, matching the day's low at the opening price. The stock is trading near its 52-week high of ₹1,421.49, significantly above its 52-week low of ₹1,020.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Dr. Reddy's and Alvotech partner to develop and commercialize Biosimilar to Keytruda
Dr. Reddy's and Alvotech partner to develop and commercialize Biosimilar to Keytruda

Business Upturn

time3 hours ago

  • Business Upturn

Dr. Reddy's and Alvotech partner to develop and commercialize Biosimilar to Keytruda

By Aman Shukla Published on June 5, 2025, 08:41 IST Dr. Reddy's Laboratories Ltd., a leading Indian pharmaceutical company, has entered into a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilar medicines. The partnership aims to co-develop, manufacture, and commercialize a biosimilar version of Keytruda® (pembrolizumab), a groundbreaking cancer treatment used for multiple cancer types worldwide. Keytruda® is a highly successful immunotherapy drug, with global sales reaching an impressive US$29.5 billion in 2024. By combining their expertise, Dr. Reddy's and Alvotech plan to accelerate the biosimilar's development timeline and expand its availability across international markets. Under the agreement, both companies will share development costs and responsibilities, ensuring efficient manufacturing and distribution. Each partner retains the right to commercialize the biosimilar globally, with certain exceptions, maximizing reach and impact. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store